Baseline blood levels before CPAP treatment
| Cardiovascular marker | Pre subtherapeutic CPAP(n = 112) | Pre therapeutic CPAP(n = 108) | Normal controls |
|---|---|---|---|
| Values are mean (SD). | |||
| †No laboratory reference range as new test. | |||
| ‡Compared with all OSA patients before randomisation. | |||
| ¶Non-fasting levels. | |||
| FXIIa (ng/ml)† | 2.0 (1.2), n = 19 | 2.1 (1.0), n = 26 | 1.7 (0.3), n = 21 |
| p<0.001‡ | |||
| FVIIa (mU/ml)† | 111.2 (40.8), n = 18 | 93.7 (50.7), n = 26 | 32.0 (14.0), n = 32 |
| p<0.001‡ | |||
| s-Psel (ng/ml)† | 53.0 (32.3), n = 46 | 58.2 (41.9), n = 47 | 29.5 (10.5), n = 22 |
| p = 0.005‡ | |||
| TAT (μg/l)† | 12.3 (24.1), n = 20 | 12.3 (25.1), n = 26 | 2.6 (1.4), n = 29 |
| p = 0.007‡ | |||
| Laboratory reference ranges | |||
| vWFAg (IU/dl) | 120.8 (50.5), n = 46 | 129.3 (51.2), n = 44 | 50–200 |
| Fibrinogen (g/l) | 2.6 (0.6), n = 20 | 2.4 (0.5), n = 26 | 1.5–4.0 |
| FVII (IU/dl) | 118.4 (20.8), n = 20 | 119.5 (28.3), n = 26 | 50–200 |
| FVIII (IU/dl) | 124.1 (29.3), n = 20 | 130.8 (31.6), n = 26 | 50–200 |
| FXII (IU/dl) | 102.9 (29.5), n = 20 | 124.2 (36.8), n = 26 | 50–200 |
| Homocysteine (μmol/l) | 9.7 (3.6), n = 49 | 9.9 (3.2), n = 52 | 5–15 |
| Cholesterol (mmol/l) | 5.7 (1.1), n = 107 | 5.6 (1.3), n = 106 | 3.9–7.8 |
| Triglyceride (mmol/l) | 2.6 (1.9)¶, n = 49 | 3.3 (2.5)¶, n = 52 | 0.55–1.9 (fasting) |